Anhydrous Cyclophosphamide

• BreAK CRC (001) trial Recruiting
  2024-512011-45-00 Phase I (FiH) 2 countries Brenus Pharma
• Stem cell transplantation in diffuse cutaneous systemic sclerosis: upfront therapy or rescue therapy after failure of immunosuppressants Recruiting
  2023-505877-34-00 Phase IV 3 countries University Medical Center Utrecht
• REPROGRAM-02 : Induction Regorafenib in combination with metronomic cyclophosphamide, capecitabine, and low-dose aspirin followed by chemoth… Recruiting
  2024-516709-22-00 Phase II/III 1 country Centre Hospitalier Regional Universitaire
• CARE : Impact of Regorafenib in combination with multimodal metronomic chemotherapy (cyclophosphamide, capecitabine, and low-dose aspirin) o… Recruiting
  2023-509761-21-00 Phase III 1 country Centre Hospitalier Regional Universitaire
• International multicenter, open-label clinical trial for the treatment of acute myeloid leukemia in children and adolescents Recruiting
  2022-500783-35-00 Phase III 6 countries GPOH gGmbH
• Allogeneic hematopoietic cell transplantation from HLA-matched donor after Flu-Mel-PTCy versus Flu-Mel-ATG reduced-intensity conditioning: a… Recruiting
  2024-518568-11-00 Phase II 1 country Centre Hospitalier Universitaire De Liege
• Randomized double blind double dummy control trial comparing the safety and efficacy of rituximab versus oral cyclophosphamide in severe for… Ended
  2024-514885-38-00 Phase III 1 country Centre Hospitalier Universitaire Rouen
• A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended
  2022-501259-10-00 Phase II 7 countries Kite Pharma Inc.
• A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended
  2022-501260-18-00 Phase II 7 countries Kite Pharma Inc.
• A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancie… Ended
  2022-501261-46-00 Phase II 7 countries Kite Pharma Inc.
• A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended
  2022-501262-21-00 Phase II 7 countries Kite Pharma Inc.
• Phase 2 study of pembrolizumab and chemotherapy in participants with classical Hodgkin Lymphoma that has just been diagnosed Ended
  2022-501615-14-00 Phase II 4 countries Merck Sharp & Dohme LLC
• A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma Ended
  2023-505169-10-00 Phase II 1 country Kite Pharma Inc.
• A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy … Ended
  2022-501382-49-00 Phase III 8 countries Merck Sharp & Dohme LLC
• A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexametha… Ended
  2024-511967-26-00 Phase III 11 countries Janssen Cilag International
• A Phase II study evaluating efficacy of KTE-X19 CAR-T cell therapy in Relapsed or Refractory Mantle-Cell Lymphoma achieving a partial respon… Expired
  2022-502907-31-00 Phase II 1 country Fondazione IRCCS Istituto Nazionale Dei Tumori

Showing 1–16 of 16 trials